Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). (Q53352963)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

randomized experiment

1 reference

based on heuristic

inferred from title

author name string

M Gershanovich

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

H A Chaudri

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

D Campos

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

H Lurie

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

A Bonaventura

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

M Jeffrey

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

F Buzzi

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

I Bodrogi

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

H Ludwig

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

P Reichardt

10

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

N O'Higgins

11

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

G Romieu

12

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

P Friederich

13

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

M Lassus

14

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

publication date

1 June 1998

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

639-645

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

randomized experiment

0 references

Megestrol acetate versus aminoglutethimide for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine therapy of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine treatment of breast cancer in women

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of aromatase in vitro and in vivo by aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

An in vivo model of intratumoural aromatase using aromatase‐transfected MCF7 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008226721932

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008226721932

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9681078

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53352963&oldid=1504879488"